NewAmsterdam Pharma (NASDAQ:NAMSW) Short Interest Update

NewAmsterdam Pharma (NASDAQ:NAMSW) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 12,100 shares, a growth of 21.0% from the May 31st total of 10,000 shares. Based on an average daily volume of 5,500 shares, the days-to-cover ratio is currently 2.2 days.

NewAmsterdam Pharma Trading Up 15.4 %

NASDAQ NAMSW traded up $1.39 on Tuesday, reaching $10.40. The company had a trading volume of 8,765 shares, compared to its average volume of 12,671. NewAmsterdam Pharma has a 52 week low of $0.99 and a 52 week high of $14.67. The stock’s 50 day moving average is $9.22 and its 200-day moving average is $8.69.

Institutional Inflows and Outflows

An institutional investor recently raised its position in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC lifted its position in shares of NewAmsterdam Pharma (NASDAQ:NAMSW) by 47.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 202,599 shares of the company’s stock after buying an additional 65,599 shares during the period. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $2,237,000 at the end of the most recent quarter.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.